Schrödinger (SDGR) Jefferies London Healthcare Conference 2025 summary

Business model and platform differentiation

• Focuses on computational and physics-based simulation for molecular discovery, supplementing experimental data for drug discovery applications.

• Monetizes platform through software licensing, pharma collaborations, and proprietary drug discovery programs, with over 1,700 customers and 19 active collaborations.

• Differentiates by integrating physics-based methods with AI, enabling accurate molecular property computation without reliance on large training sets.

• Platform is therapeutic area agnostic, supporting diversification across immunology, oncology, and other significant disease areas.

Financial performance and strategic updates

• Reported $54 million in quarterly revenue, up 54% year over year, with $40.9 million from software and $13.5 million from drug discovery.

• Maintains $250 million annual revenue guidance, with a shift toward increased drug discovery revenue and slightly reduced software revenue.

• Transitioning to an R&D-focused model, aiming to complete dose escalation studies and seek partners for further clinical development, avoiding advancing internal assets to IND stage.

• Generated $600 million in the last five years from upfronts, company sales, and milestones, with $5 billion in potential milestones across 15 programs.

• Ended the quarter with $401 million in cash, implemented $30 million in expense reductions, and expects $40 million in savings from winding down clinical programs.

Partnerships and pipeline progress

• Expanded pharma partnerships with companies like BMS, Lilly, and Novartis, leading to increased platform adoption and milestone revenues.

• 15 programs eligible for milestones or royalties, with ongoing efforts to present data from key clinical programs (3515 and 1505) in the coming year.

• MALT1 program showed strong safety and efficacy in phase one, with 100% response in Waldenstrom's and activity in other cancers; seeking partners for further development.

• Wee1/Myt1 co-inhibitor in dose escalation, aiming to demonstrate efficacy and improved safety in solid tumors, with data expected in the first half of next year.

• Strategic shift prioritizes preclinical discovery and partnerships over internal clinical development to optimize capital and focus on core strengths.